NCT04457258Active, not recruitingEarly phase 1
68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma
PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Sarcoma: An Exploratory Biodistribution Study With Histopathology Validation
Source: ClinicalTrials.gov · Last updated 17 Sept 2026
Brief summary (registry, in English)
This early phase I trial studies an imaging technique called 68Ga-FAPi-46 PET/CT to determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with sarcoma. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 68Ga-FAPi. Because some cancers take up 68Ga-FAPi it can be seen with PET. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient's body.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- First submitted
- 30 Jun 2020
- Start date
- Sept 2020
- Primary completion date
- Dec 2026
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Diseases
- Sarcoma
- NCT number
- NCT04457258
What you commit to
- Study type: Interventional · Early phase 1
- Participants enrolled: 18
- From Sept 2020 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with any new cancer therapy between the baseline 18F-FDG PET/CT and the investigational FAPI PET/CT
- Patient has underlying disease which, based on the judgment of the investigator, might interfere with the collection of high quality data.
Other
- Patient is pregnant or nursing.
Who the study is looking for
- Patients who are scheduled to undergo surgical excision or biopsy of a suspected sarcoma primary, or a suspected recurrent or metastatic lesion.
- Patients who are ≥ 18 years old at the time of the radiotracer administration.
- Patients who can provide written informed consent.
- Patients who are able to remain still for duration of imaging procedures (up to one hour for each).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UCLA / Jonsson Comprehensive Cancer Center Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.